Posted: 2014-04-30 in Press Releases
MiReven Receives United States Patent
Perth, Western Australia (30 April, 2014) - MiReven Pty Ltd (mireven.com.au), an Australian microRNA company commercialising discoveries from the Harry Perkins Institute of Medical Research on the anti-cancer potential of miR-7, announces today the grant of its first patent by the United States Patent Office.
The granted US patent, ‘Method Of Modulation of Expression of Epidermal Growth Factor Receptor (EGFR) Involving miRNA’, covers the work of MiReven’s founding scientists Prof. Peter Leedman and Dr Keith Giles on the anti-cancer potential of micro RNA-7 (miR-7), who along with Dr Rebecca Webster, are named inventors on the patent.
MiReven has worldwide exclusive rights to the patent through its technology licence from the University of Western Australia, as well as to other miR-7-related patent applications at various stages of prosecution in key markets around the world.
miR-7 is part of a recently discovered family of small, regulatory molecules that have the ability to regulate families of genes inside cells. miR-7 regulates genes involved in cancer and resistance to cancer therapy. By developing miR-7 as a ‘miR-replacement therapy’, MiReven hopes to provide additional therapeutic options for difficult to treat cancers.
Professor Peter Leedman, Director of the Perkins Institute and co-inventor of the MiReven patents, said, ‘The granting of our first US patent is a milestone in the development of MiReven’s growing intellectual property portfolio. The patent also validates the Institute’s parallel strategies of high-profile scientific publication output combined with protection of intellectual property value, without which our discoveries cannot be translated into potentially life-saving developments in cancer therapy.”
MiReven is a private company funded by investments from the Medical Research Commercialisation Fund (MRCF). Dr Stephen Thompson, MiReven’s Chairman and MRCF representative on the Board of Directors, added, “miR-7 replacement therapy is an exciting new approach in cancer therapeutic development. MiReven is developing a robust intellectual property portfolio on the anti-cancer potential of miR-7 and we have additional patent families currently being prosecuted which all add significant value to our IP estate.”
The patent can be accessed online at http://www.lens.org/lens/patent/US_8673872_B2
|Enquiries||Christopher Wraight PhD MBA|
|Technology Advisor & Manager|
|Tel: +61 3 9657 0700|
miR-7: An anti-cancer micro RNA, and MiReven Pty Ltd MiReven is a biopharmaceutical company focused on developing miR-7 as a cancer therapy. The Company was formed in 2010 through an investment from the Medical Research Commercialisation Fund (MRCF). The Company’s published research shows that miR-7 can knock-out an essential growth receptor for cancer, known as the epidermal growth factor receptor (EGFR), as well as its associated signaling pathways that promote cancer development. EGFR is a major target for cancer therapy because it is often associated with disease progression, resistance to chemotherapy and radiation therapy.
The Medical Research Commercialisation Fund (MRCF) The $51 million Medical Research Commercialisation Fund (MRCF) Collaboration is an innovative investment collaboration established in 2007 and managed by Brandon Capital Partners (www.brandoncapital.com.au). The MRCF invests in early stage development and commercialisation opportunities emanating from its membership of 32 Australian medical research institutes and allied research hospitals, which includes The Harry Perkins Institute of Medical Research. The MRCF IIF, LP fund is supported by AustralianSuper, StatewideSuper and the Australian Government under its IIF program. The MRCF also acknowledges the support of the State Governments of Victoria, New South Wales, Western Australia and Queensland.
The Harry Perkins Institute of Medical Research is Western Australia's premier adult medical research institute, investigating the genetic and environmental causes of a range of diseases. Formed in 1998 with a vision of fostering a high-level of collaboration between the State's medical researchers, our team has made, and continues to make, a number of internationally-important discoveries with the potential to deliver better health to the global community. The Harry Perkins Institute is located at the Queen Elizabeth II Medical Centre, Nedlands.
The University of Western Australia Established in 1911, UWA is a research-intensive university ranked 91 in the world, 26 for Life & Agricultural Sciences and 51 to 75 for Clinical Medicine & Pharmacy, in the highly respected Shanghai-Jiao Tong University's Academic Ranking of World Universities in 2013. As Western Australia's premier university, UWA is a member of the prestigious ‘Group of Eight’-a coalition of the top research universities in Australia- and one of only two Australian universities to belong to the Worldwide Universities Network, a partnership of 18 research-led universities from Europe, North America, North Asia, Australia and Africa. The commercialisation of intellectual property from The Harry Perkins Institute of Medical Research is facilitated through UWA’s Office of Industry & Innovation.